View Older Stories View More Recent Stories

Feb 5, 2026 10:25AM Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
Feb 5, 2026 10:24AM Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
Feb 5, 2026 10:10AM Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
Feb 5, 2026 09:58AM BMO Capital: 'Novo Mgmt Meetings Highlight Deep Strategic Challenges'
Feb 5, 2026 09:08AM Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
Feb 5, 2026 09:01AM Hims & Hers adds compounded semaglutide pills starting at $49 monthly
Feb 5, 2026 08:52AM Hims & Hers Health (HIMS) launches a copy of Wegovy pill at $49/month
Feb 4, 2026 09:07AM HIMS launches multi-cancer screening blood test through GRAIL partnership
Jan 20, 2026 04:53AM Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
Jan 12, 2026 06:01AM Evercore ISI Starts Hims and Hers (HIMS) at In Line
Jan 8, 2026 05:14AM Hims and Hers (HIMS) PT Lowered to $29 at BofA Securities, 'Sales and EBITDA margin expectations are too high'
Dec 19, 2025 05:12AM BofA on Hims and Hers (HIMS): 'November data: Sales steady, orders still weaker, and December will determine 4Q'
Dec 10, 2025 04:07AM Hims & Hers launches weight loss program in UK with Hers platform
Dec 8, 2025 07:30AM Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS), PT $37, 'Q4 revenues tracking below guidance and consensus'
Dec 4, 2025 09:19AM Hims and Hers (HIMS) PT Lowered to $41 at Leerink Partners
Dec 4, 2025 07:00AM Hims & Hers expands into Canada through Livewell acquisition
Dec 4, 2025 07:00AM HIMS enters Canada market through Livewell acquisition
Nov 17, 2025 07:46AM Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
Nov 17, 2025 06:01AM Hims & Hers appoints Deb Autor as first chief policy officer
Nov 13, 2025 12:00PM HIMS launches Labs testing service with two pricing tiers
Nov 13, 2025 11:47AM Truist: 'Klarna Partnership Aligns with HIMS' Focus on Improving Affordability'
Nov 13, 2025 11:45AM Hims & Hers Health, Inc. (HIMS) To Offer Lab Testing To Boost Growth - DJ
Nov 12, 2025 06:41AM Morgan Stanley on Hims and Hers (HIMS): 'October Data Continues to Trend in the Wrong Direction'
Nov 6, 2025 01:17PM Needham: 'GLP-1 Price Cuts Limit HIMS Competitive Advantage'
Nov 4, 2025 09:34AM Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
Nov 4, 2025 08:06AM Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'
Nov 4, 2025 06:22AM Hims and Hers (HIMS) PT Raised to $46 at Leerink Partners
Nov 4, 2025 06:06AM KeyBanc: 'Hims and Hers (HIMS) Setting the Stage for Future Growth'
Nov 4, 2025 05:13AM Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'
Nov 4, 2025 05:10AM Hims and Hers (HIMS) PT Raised to $32 at BofA Securities
Nov 4, 2025 04:35AM BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'
Nov 4, 2025 03:20AM Canaccord Genuity Reiterates Buy Rating on Hims and Hers (HIMS)
Nov 3, 2025 04:41PM After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
Nov 3, 2025 04:10PM Hims & Hers in talks with Novo Nordisk to offer Wegovy treatments
Nov 3, 2025 04:09PM Hims & Hers Health, Inc. (HIMS) Misses Q3 EPS by 4c, Offers Guidance
Nov 3, 2025 10:17AM Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
Oct 31, 2025 10:29AM Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
Oct 31, 2025 04:26AM Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put into quarter results
Oct 28, 2025 09:03AM TD Cowen on Hims and Hers (HIMS): 'Decelerating Trends; Lack of Upside Likely'
Oct 21, 2025 04:35AM KeyBanc Starts Hims and Hers (HIMS) at Sector Weight
Oct 20, 2025 11:42AM Hims & Hers CEO Dudum comments on Grail investment
Oct 15, 2025 10:07AM BofA: 'We maintain our Underperform rating on HIMS due to growing competition, but view this morning’s news positively'
Oct 15, 2025 09:03AM Hims & Hers launches menopause treatment services
Oct 15, 2025 08:51AM Hims & Hers to Offer Treatments for Menopause, Perimenopause - DJ
Oct 10, 2025 06:14AM BofA Negative on Hims and Hers (HIMS): 'Lowering 4Q sales and full year below the guidance range'
Oct 9, 2025 09:05AM Hims & Hers releases customer survey data on telehealth care quality
Oct 2, 2025 04:23PM Hims & Hers CEO Dudum announces COO change, appointing Mike Chi
Oct 2, 2025 04:07PM Hims & Hers names Mike Chi as new COO as Nader Kabbani transitions
Oct 1, 2025 06:24AM BofA Reiterating Negative View on Hims and Hers (HIMS): '3Q beat less likely, order growth under more pressure'
Sep 24, 2025 08:34AM Survey shows 1/3 of GLP-1 users are lower-income
View More Recent Stories View Older Stories